Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) — The “Glucagon-like Peptide 1 Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The glucagon-like peptide 1 (GLP-1) market has witnessed robust growth, expanding from $22.06 billion in 2025 to an expected $23.88 billion in 2026, at a compound annual growth rate (CAGR) of 8.2%. This growth is driven by the increasing prevalence of diabetes and obesity, the acceptance of injectable peptide therapies, and the availability of branded GLP-1 drugs. By 2030, the market is set to reach $33.26 billion, maintaining a CAGR of 8.6%. Factors fueling this expansion include rising demand for weight management therapies, advancements in peptide drug innovation, and the focus on chronic disease management and personalized medicine.
The emphasis on personalized medicine is especially pivotal, allowing for customized GLP-1 formulations tailored to individual patient needs. The Personalized Medicine Coalition announced a significant upsurge in FDA-approved personalized treatments in 2023. This progress contributes significantly to the GLP-1 market’s growth.
Key market players, such as Novo Nordisk A/S, Eli Lilly, and Pfizer, are focusing on technological advancements to enhance the safety and convenience of GLP-1 therapies in diabetes care and weight management. A notable development is the launch of Wegovy by Novo Nordisk A/S in March 2024, the first once-weekly GLP-1 therapy designed to manage weight effectively, showcasing a safe and convenient approach for patients.
Novo Holdings A/S’s acquisition of Catalent Inc. for $16.5 billion in March 2024 marks a significant strategic move to bolster its presence in the GLP-1 market. Leveraging Catalent’s advanced infrastructure in fill-finish manufacturing, this acquisition aims to meet the surging demand for diabetes and weight management treatments.
Prominent players in the GLP-1 market include Novo Nordisk, Eli Lilly and Company, Pfizer Inc., AstraZeneca Plc, and others. These companies are key contributors to the growing market landscape, continuously innovating to meet the evolving needs of patients.
Geographically, North America dominated the GLP-1 market in 2025, with Asia-Pacific, Western Europe, and other regions playing significant roles. Countries involved in this market include the USA, China, Germany, India, and Australia, among others.
The market involves the sales of drugs like dulaglutide, albiglutide, semaglutide, and tirzepatide, with values representing ‘factory gate’ prices-direct sales by manufacturers, impacting market dynamics substantively. Market value encompasses all revenues from sales, grants, or donations within specific geographies, underlining its robustness and future potential.
Report Scope
Markets Covered:
- Product: Trulicity, Ozempic, Victoza, Rybelsus, and others.
- Route of Administration: Oral, Parenteral, and others.
- End-Users: Hospitals, Specialty Clinics, and others.
Subsegments:
- Trulicity: Injections with varying dosage forms.
- Ozempic and Victoza: Pre-filled pen injections with multiple dosages.
- Rybelsus: Oral tablets in different dosages.
- Other Types: Experimental formulations and combination products.
Key Companies Mentioned: Featuring significant industry players like Novo Nordisk, Eli Lilly, Pfizer, AstraZeneca
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026 – 2030 |
| Estimated Market Value (USD) in 2026 | $23.88 Billion |
| Forecasted Market Value (USD) by 2030 | $33.26 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Global |
Key Topics Covered:
1. Executive Summary
1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market
2. Glucagon-like Peptide 1 Market Characteristics
2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Glucagon-like Peptide 1 Market Attractiveness Scoring and Analysis
2.4.1. Overview of Market Attractiveness Framework
2.4.2. Quantitative Scoring Methodology
2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment and Risk Profile Evaluation
2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations
3. Glucagon-like Peptide 1 Market Supply Chain Analysis
3.1. Overview of the Supply Chain and Ecosystem
3.2. List of Key Raw Materials, Resources & Suppliers
3.3. List of Major Distributors and Channel Partners
3.4. List of Major End Users
4. Global Glucagon-like Peptide 1 Market Trends and Strategies
4.1. Key Technologies & Future Trends
4.1.1 Biotechnology, Genomics & Precision Medicine
4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
4.1.3 Industry 4.0 & Intelligent Manufacturing
4.1.4 Sustainability, Climate Tech & Circular Economy
4.1.5 Artificial Intelligence & Autonomous Intelligence
4.2. Major Trends
4.2.1 Rising Adoption of Glp-1 Therapies for Obesity Management
4.2.2 Increasing Development of Oral Glp-1 Formulations
4.2.3 Growing Focus on Long-Acting Peptide Drugs
4.2.4 Expansion of Combination Therapy Approaches
4.2.5 Enhanced Patient-Centric Drug Delivery Systems
5. Glucagon-like Peptide 1 Market Analysis of End Use Industries
5.1 Hospitals
5.2 Specialty Clinics
5.3 Diabetes Care Centers
5.4 Pharmaceutical Companies
5.5 Research and Academic Institutes
6. Glucagon-like Peptide 1 Market – Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, and Covid and Recovery on the Market
7. Global Glucagon-like Peptide 1 Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
7.1. Global Glucagon-like Peptide 1 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Glucagon-like Peptide 1 Market Size, Comparisons and Growth Rate Analysis
7.3. Global Glucagon-like Peptide 1 Historic Market Size and Growth, 2020-2025, Value ($ Billion)
7.4. Global Glucagon-like Peptide 1 Forecast Market Size and Growth, 2025-2030, 2035F, Value ($ Billion)
8. Global Glucagon-like Peptide 1 Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
Companies Featured
- Novo Nordisk
- Eli Lilly And Company
- Pfizer Inc.
- AstraZeneca Plc
- Sanofi S.A.
- Boehringer Ingelheim International GmbH
- Merck And Co., Inc.
- Takeda Pharmaceutical Company Limited
- Roche Holding AG
- Johnson And Johnson
- Amgen Inc.
- GlaxoSmithKline Plc
- Novartis AG
- Bayer AG
- AbbVie Inc.
- Bristol Myers Squibb Company
- Biocon Limited
- Hanmi Pharmaceutical Co., Ltd.
- Innovent Biologics, Inc.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Zealand Pharma A/S
- Gan And Lee Pharmaceuticals Co., Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/6ldfe6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Glucagon-like Peptide 1 Market
